Webcast: Addressing Analytics Costs and Inefficiencies
Celent research reveals in-house strategies for OTC pricing will require investments between $25 to $36 million
Join Cubillas Ding, Celent's Research Director and author of the recent report titled "Optimizing the OTC Pricing and Valuation Infrastructure" as well as Bob Park, FINCAD's President and CEO as they discuss the challenges firms face when building their own derivatives analytics library.
In this informative webcast, find out what is driving firms to re-examine the build versus buy decision. Discover the steps that organizations can take to improve Total Cost of Ownership and Return on Investment.
"Despite the significant costs, most organizations are largely unaware of how much they really spend on analytics at a firmwide level, especially taking into account indirect costs, inefficiencies, and integration expenditures," Cubillas Ding, Research Director, Celent.
View the Webcast to:
- Identify cost-accumulating areas that may be hampering your organization
- Discover key steps your organization can take to improve ROI
- Re-examine how internal development efforts bring differentiation
Part 1
Part 2